MedTrace Logo

NAD Supplementation to Reduce the Incidence of Cardiac Surgery Associated Acute Kidney Injury

NCT07739290 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-07-31

No results posted yet for this study

Summary

The purpose of this single-center, randomized, double-blinded placebo-controlled pilot trial is to demonstrate feasibility and help design a larger trial to assess the effectiveness of nicotinamide (NAM) supplementation in reducing risk of post-operative AKI in patients undergoing cardiac surgery.

Conditions

Interventions

DIETARY_SUPPLEMENT

Nicotinamide (NAM)

A one time 3000 mg nicotinamide dose administered orally on the morning of cardiac surgery

DIETARY_SUPPLEMENT

Placebo control

A visually identically placebo

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-01
Primary Completion
2028-10-01
Completion
2029-01-01

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07739290 on ClinicalTrials.gov